Orphazyme Tumbles Back To Earth As FDA Rejects Arimoclomol
Drug Turned Down For NPC
Following a week of "insane trading" which saw the Danish stock soar based on social media chatter, US regulators have surprised the firm and investors by issuing a complete response letter for arimoclomol for Niemann-Pick disease type C.
